Why Language Really Matters?

Why Language Really Matters?

John Nosta 25/08/2021
Why Language Really Matters?

Swell and lousy.

According to Lucy's erudite and pedantic teacher, these are two words you should never use. Never.

So, I think that this guy with the bow tie might be able to teach the life science industry a thing or two about itself.

Words matter.

We don't often see words like 'swell' or 'lousy' in the traditional pharmaceutical lexicon. But we frequently see another two words that, I believe, are downright lousy! Words that have infiltrated the life science dialogue to the point that most professionals see them as benign terms of the trade.

Those words are 'trial' and 'recruitment'.

If you're not familiar with the context, both words are associated with drug trials where patients are recruited for enrollment in a scientific study to evaluate a drug. The very task of getting patients into these clinical studies is very difficult. Aside from an underlying illness that might be life threatening, the associated tasks of regular exams and blood tests (to name a few) make it an uphill battle for both pharma and patient. In fact, new options for finding and engaging patients are top of mind for many contract research organizations and pharmaceutical companies.

Clinical trials are vital. They are the lifeblood of drug development. But as difficult as the task may be, the studies are encumbered by language and these two 'lousy' words that make me crazy.

Let's start with the word 'trial'. One trip to the dictionary or just to your imagination and clearly it's something that you would like to avoid. Either you're on trial--a formal examination before a judge or jury to determine guilt and punishment--or you're subjected to the trials and tribulations of life's difficult situations. Either way, it ain't optimal.

How about recruitment? Your instantaneous word association can certainly conjure the feelings of enlisting in the military service, heading to battle, and putting your life at risk.

Interestingly, drug trials are battles. And the drug will stand before a jury of clinicians, administrators, and regulators. But I wonder if these are the best words that we can choose to foster patient engagement? Is psychopathology working to the advantage of the life science industry or against it? From politics to conversation, a simple word or phrase can make a huge difference in communicating a point. I believe that it might be time for pharma to think about this too.

I hope Lucy remembers how insidious those two words can be--how they define your status in life for better or worse. And maybe, the life science industry can follow along.

Lucy_Video.png

 

Share this article

Leave your comments

Post comment as a guest

0
terms and condition.
  • No comments found

Share this article

John Nosta

Digital Health Expert

John is the #1 global influencer in digital health and generally regarded as one of the top global strategic and creative thinkers in this important and expanding area. He is also one the most popular speakers around the globe presenting his vibrant and insightful perspective on the future of health innovation. His focus is on guiding companies, NGOs, and governments through the dynamics of exponential change in the health / tech marketplaces. He is also a member of the Google Health Advisory Board, pens HEALTH CRITICAL for Forbes--a top global blog on health & technology and THE DIGITAL SELF for Psychology Today—a leading blog focused on the digital transformation of humanity. He is also on the faculty of Exponential Medicine. John has an established reputation as a vocal advocate for strategic thinking and creativity. He has built his career on the “science of advertising,” a process where strategy and creativity work together for superior marketing. He has also been recognized for his ability to translate difficult medical and scientific concepts into material that can be more easily communicated to consumers, clinicians and scientists. Additionally, John has distinguished himself as a scientific thinker. Earlier in his career, John was a research associate at Harvard Medical School and has co-authored several papers with global thought-leaders in the field of cardiovascular physiology with a focus on acute myocardial infarction, ventricular arrhythmias and sudden cardiac death.

   
Save
Cookies user prefences
We use cookies to ensure you to get the best experience on our website. If you decline the use of cookies, this website may not function as expected.
Accept all
Decline all
Read more
Analytics
Tools used to analyze the data to measure the effectiveness of a website and to understand how it works.
Google Analytics
Accept
Decline